María Jesús Perugorria Montiel-rekin lankidetzan egindako argitalpenak (18)

2022

  1. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

2021

  1. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376

2020

  1. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets

    Liver International, Vol. 40, Núm. 7, pp. 1670-1685

2019

  1. Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage

    Gut, Vol. 68, Núm. 3, pp. 533-546

2018

  1. MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis

    Cell Death and Disease, Vol. 9, Núm. 10

  2. MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation

    Hepatology, Vol. 67, Núm. 4, pp. 1420-1440

  3. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1468-1477

2017

  1. Novel lncRNA T-UCR as a potential downstream driver of the Wnt/β-catenin pathway in hepatobiliary carcinogenesis

    Gut

  2. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma

    Journal of Hepatology, Vol. 67, Núm. 1, pp. 72-83

2014

  1. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases

    Gut, Vol. 63, Núm. 10, pp. 1658-1667

2009

  1. Amphiregulin Induces the Alternative Splicing of p73 Into Its Oncogenic Isoform ΔEx2p73 in Human Hepatocellular Tumors

    Gastroenterology, Vol. 137, Núm. 5

  2. Inflammation and liver cancer: New molecular links

    Annals of the New York Academy of Sciences

  3. The epidermal growth factor receptor ligand amphiregulin is a negative regulator of hepatic acute-phase gene expression

    Journal of Hepatology, Vol. 51, Núm. 6, pp. 1010-1020

  4. The epidermal growth factor receptor: A link between inflammation and liver cancer

    Experimental Biology and Medicine

  5. Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy

    Cancer Research, Vol. 69, Núm. 4, pp. 1358-1367

2008

  1. The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis

    Hepatology, Vol. 48, Núm. 4, pp. 1251-1261

2007

  1. Amphiregulin: A new growth factor in hepatocarcinogenesis

    Cancer Letters, Vol. 254, Núm. 1, pp. 30-41

2006

  1. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells

    Cancer Research, Vol. 66, Núm. 12, pp. 6129-6138